It’s turning out to
be one of the biggest epidemic waves in American history, with estimated costs
nationally jumping approximately 40% in just the past 5 years, to roughly $1/4
trillion annually. The epidemic is diabetes, and the size and scope of the
problem, including the disastrous drain on the country’s economy, is just now
beginning to be fully appreciated. Less obvious and dramatic than high-profile
diseases such as cancer, the hidden power behind the diabetes epidemic is that
it affects so many people. It is now estimated that over 25 million Americans
have the disease, though many are not aware of it, with nearly 80 million Americans
in a state of prediabetes. Diabetes complications include heart disease,
stroke, kidney damage, and retinopathy.
Driven, it is
believed, by a generation of negative dietary and life style habits, diabetes
is now becoming one of America’s primary healthcare targets. Unfortunately,
such habits, and the industries that support them, are slow to change, and
today there is a desperate need for medical technologies that can help stem the
epidemic tide more quickly.
Boston Therapeutics
believes it has developed the most effective single solution with PAZ320, the
company’s non-systemic, non-toxic, chewable drug candidate for prevention of
diabetes and its complications. The drug is currently undergoing clinical
trials after getting promising results in initial studies. PAZ320 would be a
miracle to millions of diabetic and prediabetic patients, or anyone seeking to
better manage blood glucose levels, by inhibiting the enzymes that release
glucose from complex carbohydrates in foods during digestion. As a result, the
drug now has a near-term opportunity in what is already a $35 billion diabetes
drug market.
PAZ320 is not Boston
Therapeutic’s only product. They are also in pre-clinical stage development of
IPOXYN, an injectable universal oxygen carrier for the prevention of necrosis
and treatment of ischemic conditions which may lead to necrosis, and OxyFex, a
veterinary facsimile to Ipoxyn.
For additional
information, visit www.BostonTI.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment